Many patients need additional LDL-C lowering.
Add Nexlizet.1,2

Nadine’s HCP has been trying to get her LDL-C under control for 20 years

  • A
    SCVD diagnosis: Suffered an MI one year ago and her father died of an MI
  • D
    ocumented maximally tolerated statin therapy: Currently taking rosuvastatin
  • D
    idn’t achieve LDL-C goal: Needs additional LDL-C lowering to reach goal of <70 mg /dL3

CAN NEXLIZET HELP PATIENTS LIKE NADINE?

Starting LDL-C: 185 mg/dL. Adding NEXLIZET: 67 mg/dL, under Guideline recommended goal of LDL-C under 70 mg/dL

FOR PATIENTS WITH ASCVD, GUIDELINES RECOMMEND3:

  • Reducing LDL-C by ≥50%
  • Intensifying therapy if LDL-C is ≥70 mg/dL

*Maximally tolerated dose.

Results based on up to a 52% LDL-C reduction with 10-mg rosuvastatin.4

Results based on up to a 36% LDL-C reduction with NEXLIZET.1

ASCVD=atherosclerotic cardiovascular disease; HbA1c=hemoglobin A1C; LDL-C=low-density lipoprotein cholesterol; MI=myocardial infarction.

References: 1. NEXLIZET. Prescribing information. Esperion Therapeutics, Inc.; 09/2021. 2. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. J Clin Lipidol. 2016;10(5):1109-1118. 3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. 4. CRESTOR. Prescribing information. AstraZeneca; 07/2021. 5. Data on file. Protocol: ETC-1002FDC-053. August 2018.

EXPLORE THE MOA OF NEXLIZET